Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment

Medical Decision Making

Volumn 38, Issue 1_suppl, 2018, Pages 32S-43S

  Munoz, Diego F ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer simulation model; breast cancer survival; CISNET; estrogen receptor (ER) status; human epidermal growth factor 2 (HER2) status; screening mammography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; BLOOD; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; COMPUTER SIMULATION; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; FEMALE; HUMAN; MAMMOGRAPHY; MIDDLE AGED; MORTALITY; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; SURVIVAL; SURVIVAL ANALYSIS; UNITED STATES;

EID: 85040633992     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17743236     Document Type: Article

References (33)

1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
2. Berry DA, Cirrincione C, Henderson IC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658–67.
3. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991;68:2142–9.
4. Kurian AW, Carlson RW. Chapter 17: Principles of Breast Cancer Therapy. In: Li CI, ed. Breast Cancer Epidemiology: Springer; 2010:371–88.
5. Vo T, Xing Y, Meric-Bernstam F. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007;194:527–31.
6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845–56.
7. Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res. 2009;11:205.
8. Cheang MC, Voduc D, Bajdik C. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76.
9. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol. 2007;3:140.
10. Parker JS, Mullins M, Cheang MC. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.
11. Berry DA, Cronin KA, Plevritis SK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.
12. Fowble BL, Schultz DJ, Overmoyer B. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys. 1994;30:23–33.
13. Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer?ANZ J Surg. 2005;75:762–7.
14. Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155:493–502.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
16. Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
17. Slamon D, Eiermann W, Robert N. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.
18. Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Stat Med. 2007;26:581–95.
19. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006:86–95.
20. Munoz DF, XC, Plevritis SK. A molecular subtype–specific stochastic simulation model of US breast cancer incidence, survival, and mortality trends from 1975 to 2010. Med Decis Making. 2018;38(1S):89–98.
21. Alagoz O, Berry D, Feuer EJ. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Working Group (BWG) Models. Med Decis Making. 2016;Submitted.
22. Mandelblatt J, Near A, Miglioretti DL. Common model inputs in Collaborative Breast Cancer Modeling. Med Decis Making. 2016;Submitted.
23. Munoz D, Near AM, van Ravesteyn NT. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst. 2014;106(11):dju289.
24. Mandelblatt JS, Stout NK, Schechter CB. Collaborative modeling of the benefits and harms associated with different U.S. breast cancer screening strategies. Ann Intern Med. 2016;164:215–25.
25. Trentham-Dietz A, Kerlikowske K, Stout NK. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: Collaborative modeling of screening outcomes. Ann Intern Med. 2016;165:700–12.
26. Kurian AW, Munoz DF, Rust P. Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. J Clin Oncol. 2012;30:497–506.
27. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012;21:1066–77.
28. Cancer AJCo. AJCC Cancer Staging Manual. New York: Springer; 2010.
29. Freund Y ML. The alternating decision tree learning algorithm. ICML ‘99 Proceedings of the Sixteenth International Conference on Machine Learning; 1999:124-33.
30. Holmes G PB, Kirkby R, Frank E, Hall M. Multiclass alternating decision trees. ECML. 2001:161–72.
31. Gamel JW, Weller EA, Wesley MN, Feuer EJ. Parametric cure models of relative and cause-specific survival for grouped survival times. Comput Methods Programs Biomed. 2000;61:99–110.
32. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006:19–25.
33. Esserman LJ, Moore DH, Tsing PJ. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011;129:607–16.